Detecting and identifying antibiotic resistance genes in bloodstream infections
Direct detection and identification of antimicrobial resistance genes in bloodstream infections
This study is testing a new, faster way to diagnose bloodstream infections using a special tool called RaPID, which can give results in about three hours directly from patient samples, making it especially helpful for those who have already started treatment.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Helixbind, INC. NIH-funded |
| Lab location | 1 site (Boxborough, UNITED STATES) |
| Project ID | NIH-10898697 on NIH RePORTER |
What this research studies
This research focuses on improving the diagnosis of bloodstream infections (BSIs) by developing a new diagnostic platform called RaPID, which can quickly identify and characterize infections directly from patient samples without the need for traditional blood cultures. The RaPID system operates using single-use cassettes and provides results in approximately three hours, significantly faster than current methods that can take 1-3 days. This innovative approach aims to enhance the accuracy of diagnosing infections, especially in cases where patients have already received antimicrobial treatment, which can complicate traditional testing methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suspected of having bloodstream infections, particularly those who may have received prior antimicrobial treatment.
Not a fit: Patients with infections that are not bloodstream-related or those who do not have any signs of infection may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate diagnoses of bloodstream infections, ultimately improving patient outcomes and reducing hospital stays.
How similar studies have performed: Other research has shown success with similar rapid diagnostic approaches, indicating a promising potential for this novel method.
Where this research is happening
Boxborough, UNITED STATES
- Helixbind, INC. — Boxborough, United States (Active)
Researchers
- Principal investigator: Singer, Alon — Helixbind, INC.
- Study coordinator: Singer, Alon
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.